(Press-News.org) Even though the cancer-treatment agent cetuximab is not considered effective treatment for KRAS (a gene)-mutated metastatic colorectal tumors, new research indicates that patients with colorectal cancer not responding to chemotherapy and a certain variation of this gene who were treated with cetuximab had longer overall and progression-free survival than patients with other KRAS-mutations, according to a study in the October 27 issue of JAMA.
"Recent retrospective correlative analyses of metastatic colorectal cancer trials indicate that patients with KRAS-mutated tumors do not benefit from the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab and panitumumab," the authors write. However, they add there are indications that not all KRAS mutations are equal in their biological characteristics, including anecdotal reports indicating that a minority of patients with KRAS-mutated tumors can respond to anti-EGFR therapy.
Wendy De Roock, M.D., of the University of Leuven, Leuven, Belgium, and colleagues conducted a study to examine whether a certain KRAS mutation (p.G13D) may be associated with a better outcome after cetuximab treatment than observed with other KRAS mutations. The study included a pooled data set of 579 patients with chemotherapy-refractory (not responsive to treatment) colorectal cancer treated with cetuximab between 2001 and 2008 and who were included in other clinical trials or received off-study treatment. Various analyses of the data were performed. The main efficacy outcome measure was overall survival; secondary efficacy measures were response rate and progression-free survival.
The researchers found that among patients who received any cetuximab-based treatment (cetuximab monotherapy or cetuximab plus chemotherapy) (n = 571), overall and progression-free survival were significantly longer in patients with p.G13D-mutated tumors (overall survival: n=32; median [midpoint], 7.6 months; progression-free survival, n = 32; median, 4.0 months) than in patients with other KRAS-mutated tumors (overall survival: median, 5.7 months; progression-free survival: median, 1.9 months).
"In a large, retrospective pooled exploratory analysis of patients with chemotherapy-refractory colorectal cancer, we show for the first time that there is a positive association between KRAS p.G13D mutations and cetuximab treatment in regard to better overall and progression-free survival," the authors write. They add this effect may not be due to a real reduction in tumor burden but to a delay in progression.
"Prospective randomized trials are needed before conclusions about potential beneficial effects of cetuximab in p.G13D-mutated chemotherapy-refractory metastatic colorectal cancer should be inferred."
INFORMATION:
(JAMA. 2010;304[16]:1812-1820. Available pre-embargo to the media at www.jamamedia.org)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
To contact corresponding author Sabine Tejpar, M.D., Ph.D., email sabine.tejpar@uzleuven.be; for corresponding author Alberto Bardelli, Ph.D., email a.bardelli@unito.it.
For more information, contact JAMA/Archives Media Relations at 312/464-JAMA (5262) or e-mail mediarelations@jama-archives.org.
Colorectal cancer patients with gene mutation show better response to cancer agent
2010-10-27
ELSE PRESS RELEASES FROM THIS DATE:
2 clinical trials demonstrate effective weight loss strategies for obese and overweight adults
2010-10-27
Lifestyle interventions, including physical activity and structured weight loss programs, can result in significant weight loss for overweight, obese and severely obese adults, according to two reports that were posted online October 9 by JAMA. The studies and accompanying editorials were made available early online to coincide with the presentation of these papers at the 28th Annual Scientific Meeting of the Obesity Society. The articles appear in the October 27 print issue of JAMA.
According to background information in the papers, obesity is among the most significant ...
Genetic variations linked with worse outcomes with use of antiplatelet drug for cardiac procedures
2010-10-27
An analysis of data from previously published studies indicates that use of the antiplatelet drug clopidogrel for patients who have common genetic variants of a certain gene and are undergoing a procedure such as coronary stent placement have an associated increased risk for major adverse cardiovascular events, particularly development of blood clots in stents, according to a study in the October 27 issue of JAMA.
Clopidogrel, one of the most commonly prescribed medications, has been shown to reduce cardiovascular events in patients undergoing percutaneous coronary intervention ...
Better transparency needed on medical journals' competing interests
2010-10-27
Journals need to develop policies to handle the inevitable competing interests that arise when they publish papers that may bring them reprint revenue or increase their impact factors. This is the conclusion of a research article by Andreas Lundh and colleagues from the Nordic Cochrane Centre published in this weeks PLoS Medicine. An accompanying perspective by Harvey Marcovitch, ex-chair of the Committee on Publication Ethics (COPE), and an editorial from the PLoS Medicine Editors discusses this issue further, concluding that journals should apply the same degree of transparency ...
WHO pesticide regulations should be based on toxicity in humans, not rats
2010-10-27
Current WHO pesticide classifications are based on toxicity in rats but basing regulation on human toxicity will make pesticide poisoning less hazardous and prevent hundreds of thousands of deaths globally without compromising agricultural needs. These are the key findings from a study by Andrew Dawson (South Asian Clinical Toxicology Research Collaboration, University of Peradeniya, Sri Lanka) and colleagues published in this week's PLoS Medicine.
The single most common means of suicide worldwide is agricultural pesticide poisoning. The authors examined the proportion ...
Nature's backbone at risk
2010-10-27
Nagoya, Japan, Wednesday 27 October 2010 (IUCN) – The most comprehensive assessment of the world's vertebrates confirms an extinction crisis with one-fifth of species threatened. However, the situation would be worse were it not for current global conservation efforts, according to a study launched today at the 10th Conference of the Parties to the Convention on Biological Diversity, CBD, in Nagoya, Japan.
The study, to be published in the international journal Science, used data for 25,000 species from The IUCN Red List of Threatened Species™, to investigate the status ...
World's vertebrates face increasing risk of extinction
2010-10-27
A new assessment conducted by 174 scientists from around the world underscores a growing concern about the health of the world's biodiversity, quantifying the rate of decline among vertebrate species on a global scale for the first time. The team's results support the idea that our planet is currently experiencing its sixth mass extinction—nearly one fifth of all known vertebrate species are currently classified as Threatened on the International Union for the Conservation of Nature (IUCN) Red List, and an average of 52 species of mammals, birds, and amphibians move one ...
Mosquito monitoring saves lives and money, analysis finds
2010-10-27
Cutting surveillance for mosquito-borne diseases would likely translate into an exponential increase in both the number of human cases and the health costs when a disease outbreak occurs, according to an analysis by Emory University.
The Public Library of Science (PLoS) publishes the research, led by Emory disease ecologist Gonzalo Vazquez-Prokopec, Oct. 26.
"Our analysis shows that halting mosquito surveillance can increase the management costs of epidemics by more than 300 times, in comparison with sustained surveillance and early case detection," Vazquez-Prokopec ...
New snub-nosed monkey discovered in Northern Myanmar
2010-10-27
An international team of primatologists have discovered a new species of monkey in Northern Myanmar (formerly Burma.) The research, published in the American Journal of Primatology, reveals how Rhinopithecus strykeri, a species of snub-nosed monkey, has an upturned nose which causes it to sneeze when it rains.
Field biologists led by Ngwe Lwin from the Myanmar Biodiversity And Nature Conservation Association and supported by an international team of primatologists from Fauna & Flora International (FFI) and the People Resources and Biodiversity Foundation, discovered the ...
Following lifestyle tips could prevent almost a quarter of bowel cancer cases
2010-10-27
Almost a quarter of colorectal (bowel) cancer cases could be prevented if people followed healthy lifestyle advice in five areas including diet and exercise, says a new study published on bmj.com today.
Researchers from Denmark found that following recommendations on physical activity, waist circumference, smoking, alcohol and diet could reduce the risk of developing bowel cancer considerably – by 23%.
Bowel cancer is the third most common cancer in the UK where more than 38,600 people are diagnosed with the condition every year. It is the second most common cause of ...
Year-long opiate substitution for drug misusers has 85 percent chance of cutting deaths
2010-10-27
Giving people opiate substitution treatment to help with their drug addiction can lead to a 85% plus chance of reducing mortality, according to a new study published on bmj.com today.
Researchers from Bristol and London found that the length of time people had opiate substitution treatment (OST) for had a large impact on its success and the likelihood of death.
Opiate users have a high risk of death, often from overdose.
OST, mostly methadone and buprenorphine, is central to prevention of drug related mortality and often delivered in primary care settings. Over the ...